Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ranbaxy Had Smaller Recall of Generic Lipitor in August Over Pill Mix-up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/29/2012 | 06:27pm CEST
   By Peter Loftus 
 

Ranbaxy Laboratories Ltd. (500359.BY) recalled more than 32,000 bottles of its generic version of cholesterol-lowering drug Lipitor over a potential pill mix-up in August--nearly three months before a larger recall for the presence of small glass particles in some bottles.

The retail-level recall in August was triggered by a pharmacist's discovery of a 20-milligram tablet of atorvastatin--the generic name for Lipitor--inside a sealed bottle of 10-mg atorvastatin, according to details posted online this week by the U.S. Food and Drug Administration.

In an August letter to customers initiating the voluntary recall of one product lot, Ranbaxy said it couldn't rule out the possibility that the pill mix-up occurred at its facility.

The FDA has now designated the August recall as Class 2, which is reserved for situations when use of a drug may cause temporary or medically reversible health problems, or where the probability of serious adverse events is remote.

The lot recalled in August was Ranbaxy's 10-mg, 90-count tablets, with lot number 2407258 and an expiration date May 2014, according to the FDA.

Ranbaxy spokesmen couldn't immediately be reached Thursday.

The mixed-pill recall preceded a separate, larger Ranbaxy recall earlier in November of 41 lots of its generic atorvastatin, because some may have contained tiny glass particles resembling fine grains of sand. Neither Ranbaxy nor the FDA have said how many bottles in total were recalled in the latest action.

Ranbaxy, which holds more than 40% of the U.S. market for atorvastatin prescriptions, said in a press release Wednesday the probability of an adverse health event due to consumption of the tablets recalled for potential glass particles is unlikely, but can't be ruled out.

Ranbaxy said it hadn't received any reports of adverse events related to the more recent recall. The affected lot numbers in the more recent recall can be found here: http://ranbaxyusa.com/newsdisp281112.aspx.

The FDA said in a statement Thursday Ranbaxy has stopped manufacturing atorvastatin until it has investigated the cause of the glass particles and fixed the problem. The FDA said it doesn't anticipate a shortage because generic Lipitor is available from several manufacturers. But the agency is monitoring the situation and is working with other manufacturers to ensure adequate supply.

Ranbaxy was one of the first companies to begin selling generic Lipitor in the U.S. a year ago, after Pfizer Inc. (>> Pfizer Inc.) lost market exclusivity for the branded version of the drug. Pfizer's Lipitor was once the best-selling drug in the world, but sales have plummeted as it lost market share to multiple generic alternatives.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
04:33a GOP TO HIGH COURT : McAuliffe in contempt
08/31 GOP TO HIGH COURT : Hold McAuliffe in contempt
08/31 PFIZER : XALKORI® (Crizotinib) Receives Approval In European Union For The Treat..
08/31 PFIZER : Seven Hampton schools get 'mini-makeovers' this summer
08/31 $200m Halliburton cash 'blown on presidential helicopter'
08/30 U.S. slams EU, but Apple tax demand first issued in Washington
08/30DJFDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30 PFIZER : St. Louis area manufacturer of EpiPens to produce Mylan's new generic v..
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/29 PFIZER : Cypress Creek Bridge could see repairs, partial shutdown in 2020
More news
Sector news : Pharmaceuticals - NEC
12:44a SUMITOMO DAINIPPON PHARMA : Sunovion Pharma to buy Canada's Cynapsus for $624 mi..
08/31 U.S. sues to stop Deere from buying Precision Planting
08/31DJSHIRE : Files 8K - Other Events
08/31DJASTRAZENECA : Agrees to Pay $5.5 Million to Settle Alleged Bribery Probe
08/31DJASTRAZENECA : Agrees to Pay $5.5 Million to Settle Alleged Bribery Probe
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2016 52 846 M
EBIT 2016 19 400 M
Net income 2016 11 351 M
Debt 2016 19 710 M
Yield 2016 3,41%
P/E ratio 2016 19,12
P/E ratio 2017 15,80
EV / Sales 2016 4,38x
EV / Sales 2017 4,12x
Capitalization 211 570 M
More Financials
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 39,5 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
W. Don Cornwell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%211 570
JOHNSON & JOHNSON16.18%326 855
ROCHE HOLDING LTD.-12.84%214 220
PFIZER INC.7.81%211 570
NOVARTIS AG-10.02%209 772
ASTRAZENECA PLC7.33%174 031
More Results